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OBJECTIVE — Impaired glucose tolerance (IGT) is a pre-diabetic state of increasing preva-
lence among obese adolescents. The purpose of this study was to determine the natural history
of progression from normal glucose tolerance (NGT) to IGT in obese adolescents.
RESEARCH DESIGN AND METHODS — We determined the evolution of -cell func-
tion,insulinsensitivity(SI),andglucosetoleranceinamultiethnicgroupof60obeseadolescents
over the course of approximately 30 months. Each subject underwent three serial 3-h oral
glucose tolerance tests. Dynamic, static, and total -cell responsivity (d, s, and tot, respec-
tively) and Si were assessed by oral C-peptide and glucose minimal models. The disposition
index (DI), which adjusts insulin secretion for Si, was calculated.
RESULTS — At baseline, all 60 subjects had NGT. Seventy-seven percent (46 subjects) main-
tained NGT over the three testing periods (nonprogressors), whereas 23% (14 subjects) devel-
oped IGT over time (progressors). At baseline, percent fat and BMI Z score were comparable
between the groups. Fasting plasma glucose, 2-h glucose, glucose area under the curve at 180
min, and d were signiﬁcantly different between the two groups at baseline, whereas Si was
comparable between the two groups. Over time, although Si remained unchanged in nonpro-
gressors,itsteadilyworsenedby45%(P0.04)inprogressors.-Cellresponsivitydecreased
by 20% in progressors, whereas it remained stable in nonprogressors. The DI showed a progres-
sivedeclineinprogressorscomparedwithamodestimprovementinnonprogressors(P0.02).
CONCLUSIONS — ObeseadolescentswhoprogresstoIGTmaymanifestprimarydefectsin
-cell function. In addition, progressive decline in Si further aggravates -cell function, contrib-
uting to the worsening of glucose intolerance.
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U
nderstanding the underlying puta-
tivemetabolicdefectsleadingtothe
development of type 2 diabetes re-
quires studies that focus on the earliest
stages of the disease before the onset of
any alterations in glucose tolerance. In
adults, type 2 diabetes is the ﬁnal stage in
theprogressionofthedisease(1–3),char-
acterized by a progressive worsening in
both insulin resistance and secretion (4–
7). Whether a similar proﬁle also occurs
inyouthdevelopingtype2diabetesisun-
known. Much of the understanding of
type 2 diabetes in youth originates from
cross-sectional studies performed in
obese adolescents with overt disease (8)
or with impaired glucose tolerance (IGT)
(9,10). One longitudinal study in obese
adolescentswithIGTatbaselineindicated
that over a period of 23 months, 45% re-
verted to normal glucose tolerance
(NGT), 30% maintained IGT, and 25%
developed type 2 diabetes(11). Thus,
youth with IGT are at high risk for devel-
oping type 2 diabetes because of the pres-
ence of both insulin resistance and -cell
dysfunction.
To assess the metabolic sequence of
events that might be implicated in the
transition from NGT to IGT, we per-
formed serial oral glucose tolerance tests
(OGTTs) along with anthropometric
measures in a group of obese adolescents
over a period of approximately 3 years.
Using the oral minimal model (OMM)
(12,13), we determined -cell responsiv-
ity (), insulin sensitivity (Si), and dispo-
sition index (DI) and thus have repeated
measuresofbothinsulinsecretionandin-
sulin action before and during the evolu-
tion of IGT in obese adolescents. In a
longitudinal study, we tested the hypoth-
esis that preexisting -cell dysfunction,
further exacerbated by a progressive
worsening in Si, characterizes the onset of
IGT in childhood obesity.
RESEARCH DESIGN AND
METHODS— The Yale Pathophysiol-
ogy of Type 2 Diabetes in Obese Youth
Study is a long-term project aimed at
examiningearlyalterationsinglucoseme-
tabolism in obese children and adoles-
cents (14,15). The study protocol was
approved by the Human Investigations
Committee of the Yale School of Medi-
cine. Written parental consent and child
assent were obtained before the study.
The subjects were recruited from our Pe-
diatric Obesity Clinic. To be eligible for
the study, subjects had to be obese
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
From the
1Department of Pediatrics, Yale School of Medicine, New Haven, Connecticut; the
2Department of
Information Engineering, University of Padua, Padua, Italy; and the
3Yale Center for Clinical Investiga-
tion, Yale School of Medicine, New Haven, Connecticut.
Corresponding author: Sonia Caprio, sonia.caprio@yale.edu.
Received 9 July 2008 and accepted 11 December 2008.
Published ahead of print at http://care.diabetesjournals.org on 23 December 2008. DOI: 10.2337/dc08-
1274.
© 2009 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Pathophysiology/Complications
ORIGINAL ARTICLE
456 DIABETES CARE, VOLUME 32, NUMBER 3, MARCH 2009(95th percentile for age and sex) and
were excluded from this analysis if they
were using medications that may affect
glucose metabolism. Participants were
followed biannually as outpatients by the
clinical staff and received only general
standardnutritionalguidanceandrecom-
mendations for physical activity. No ap-
parent differences in adherence to these
recommendations emerged between sub-
jects. The subjects included in this analy-
sis were chosen based on having three
repeated OGTTs. In our longitudinal fol-
low-up study, the OGTT was initially re-
peated on an annual basis. In the
subsequent years, however, due to bud-
getarycutstheprotocolwasmodiﬁedand
the OGTT was repeated every 18 to 24
months.Thistimeintervalisbasedonour
previous study suggesting that changes in
categories of glucose tolerance in obese
adolescents are likely to occur over a
relatively short period of time (23
months) (11).
Forthisreport,weanalyzeddatafrom
60 obese adolescents (21 male and 39 fe-
male)fromwhomwecurrentlyhavethree
serial OGTTs and whose potential
changes in glucose tolerance over an av-
erageof30monthswewerethusableto
longitudinally assess. All 60 subjects had
NGTatbaseline.Ofthese,remarkably,46
maintained the same status during the
second and third OGTTs (nonprogres-
sors). In contrast, 14 progressed to IGT at
the third OGTT, whereas at the second
OGTT only 4 had already progressed to
IGT.Theother10werestillofNGT,albeit
at much higher levels of glucose than at
the ﬁrst OGTT. None of these subjects
had progressed to IGT and converted to
NGT, at least in this particular study.
OGTT
All subjects were invited to the Yale Cen-
ter for Clinical Investigation for an OGTT
at 8 A.M. following an overnight fast, as
previously reported (9). Baseline blood
sampleswereobtainedfromsubjectswith
the use of an indwelling venous line for
measurement of levels of glucose, insulin,
C-peptide, lipid proﬁle, free fatty acids,
adiponectin,interleukin-6,andleptin.An
OGTT was then performed with the ad-
ministration of glucose at 1.75 g/kg body
wt (maximum dose 75 g); blood samples
were obtained at 0 min and every 30 min
thereafter for 180 min for the measure-
ment of plasma glucose, insulin, and C-
peptide.
Anthropometric measurements
Total body composition was performed
using a Tanita Scale (Bioimpedance) each
time the subject came for the repeated
OGTT. Body weight was measured with a
digital scale to the nearest 0.1 kg, and
height was measured in triplicate with a
wall-mounted stadiometer at each visit.
Assessment of Si: oral glucose
minimal model
Siwasestimatedfromplasmaglucoseand
insulin concentrations measured during
the3-hOGTTusingtheoralglucosemin-
imalmodel(12,13).Simeasurestheover-
all effect of insulin on stimulating glucose
disposal and inhibiting glucose produc-
tion. This index has been validated
against the euglycemic clamp, showing a
correlation of 0.81 (P  0.001) (16).
Assessment of -cell function: oral
C-peptide minimal model
-Cell responsivity indexes were esti-
mated from plasma glucose and C-
peptide concentrations measured during
the OGTT by using the oral C-peptide
minimal model (13,17,18). Reproduc-
ibility of -cell responsivity (dynamic
[d] and static [s]) and SI from the
OMMisbetween20and30%(18),which
is very similar to that of the intravenous
glucose tolerance test. The model as-
sumes that insulin secretion is made up
of two components. A dynamic compo-
nent is likely to represent secretion of
promptly releasable insulin and is propor-
tional to the rate of glucose concentration
through a parameter, d, that deﬁnes the
dynamic responsivity index. The static
component derives from provision of new
insulintothereleasablepoolandispropor-
tional to delayed glucose through parame-
ter s.F r o md and s, one can also
calculate a single overall -cell responsivity
index. Finally, the DI is obtained by taking
theproductofandSI(DISI)(18).
Measurements of C-peptide and glu-
cose levels at 10 and 20 min of the OGTT
are critical for the modeling of -cell
function (18). In the present study, how-
ever, these early times were missing for
some of the subjects, so we used all nine
pointsobtainedduringthe180minofthe
OGTT. To test whether there is any dif-
ference between indexes calculated with
and without the early times (10 and 20
min), we examined a subset of 188 sub-
jectsfromourcohortwhoactuallyunder-
went a nine-sample 180-min OGTT
(including samples at 10 and 20 min).
This allowed us to compare results ob-
tained from a seven-sample 180-min
OGTT (without minutes 10 and 20) with
results obtained from a nine-sample 180-
min OGTT. We found that reliable esti-
mates of both Si (r  0.93, P  0.000)
and, after appropriate smoothing of glu-
cose data, total -cell responsivity (tot)
(r0.99,P000)canbeobtainedfrom
seven-sample experiments, whereas s
(r  0.93; P  000) and d (r  0. 75; P
0.001) (albeit well correlated) were 8%
underestimated and 30% overestimated,
respectively.
Statistical analyses
Demographic and anthropometric char-
acteristics at baseline were compared us-
ing Fisher’s exact and t tests. Variables
withpositivelyskeweddistributionswere
log transformed to conform to distribu-
tional assumptions required for statistical
inference. Linear trajectories from re-
peated measures of outcomes over time
were estimated by random effects regres-
sion(19).Eachoutcomewasregressedon
ﬁxed factors of time (continuous), group
(progressors vs. nonprogressors), age at
ﬁrst visit (continuous), sex, race (Cauca-
sian, African American, or Hispanic), and
ﬁrst-degreefamilyhistoryoftype2diabe-
tes (yes/no). To evaluate whether rates of
changes in outcomes varied by group, an
interaction of group by time was in-
cluded. Between-subject variability in
values of outcomes and rates of change at
0 min was permitted by the inclusion of
random effects for intercept and time,
which were also allowed to covary. Rates
of change for log-transformed variables
imply a multiplicative model, and expo-
nentiatedregressioncoefﬁcientstherefore
represent the percent change in the out-
come for a 1-month change in time. For
ease of interpretation, percent changes
over time are expressed for the approxi-
mate average time of follow-up, which
was 30 months. Models were ﬁt using
PROC MIXED in SAS v 9.1 (SAS, Cary,
NC).Pvalues0.05wereusedasthresh-
olds for signiﬁcance.
Analytical methods
Plasma glucose levels were measured us-
ing the YSI 2700 STAT analyzer (Yellow
Springs Instruments), and lipid levels
were measured using an autoanalyzer
(model 747-200; Roche-Hitachi). Plasma
insulin was measured with a radioimmu-
noassay (RIA) (Linco, St. Charles, MO)
that has 1% cross-reactivity with C-
peptideandproinsulin.PlasmaC-peptide
levels were determined with an assay by
Cali and Associates
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The intra-assay variation was 5.4% for in-
sulin and 11.6% for C-peptide, and the
interassay variation was 6.2% for insulin
and 8.47% for C-peptide. Plasma adi-
ponectin levels were measured by a dou-
ble antibody-antibody RIA from Linco by
our research laboratory. The intra- and
interassay coefﬁcients of variation were
7.1 and 9.5%, respectively. Plasma leptin
levels were measured using an RIA from
Linco. The intra- and interassay coefﬁ-
cients of variation were 6.5 and 8.0%,
respectively.
RESULTS
Differences in anthropometric and
metabolic phenotypes at baseline
between nonprogressors and
progressors
From the original cohort, 46 subjects
(77%)werefoundtohavekepttheirNGT
status at each of the three serial OGTTs
and thus are classiﬁed as nonprogressors.
In contrast, 14 subjects (23%) developed
IGT by the third OGTT and are classiﬁed
asprogressors.Thetwogroupsatbaseline
had similar age, sex, ethnicity distribu-
tion, Tanner stage of development, BMI,
and BMI Z score (Table 1). Percent total
fat tended to be higher in progressors
(P  0.07, Table 1). Whereas systolic
blood pressure was similar in the two
groups, diastolic blood pressure was
higher in progressors (P  0.049).
No signiﬁcant differences were found
in the level of proinsulin, adiponectin, in-
terleukin-6, HDL cholesterol, and tri-
glycerides. Leptin was slightly higher in
progressors (P  0.02) (Table 2). At base-
line, Si was comparable in the two groups
(Table 2); in contrast, d was signiﬁcantly
lower in progressors than in nonprogres-
sors (P0.04). No differences were noted
for s and tot. The DI tended to be
lower in progressors (P  0.14). A1C
was slightly higher in progressors (P 
0.049).
Glucose, insulin, and C-peptide
responses
Figure A1 (available in an online appen-
dix at http://dx.doi.org/10.2237/dc08-
1274) compares the changes in glucose,
insulin, and C-peptide responses in the
two groups at each of the three OGTTs.
The median (interquartile range) time for
follow-up between the ﬁrst and second
OGTT was 15.3 months (12.0–18.4) and
16.5 months (14.5–26.3) for the nonpro-
gressors and progressors, respectively,
and between the second and third OGTT
was 30.0 months (24.7–36.9) and 29.8
months (26.8–42.2), respectively. At base-
line (ﬁrst OGTT), fasting plasma glucose
levels (P  0.002) and glucose area under
the curve (AUC) (P  0.05) were signiﬁ-
cantly higher in progressors, whereas fast-
ing insulin and C-peptide, as well as the
insulin and C-peptide AUCs, were not sig-
niﬁcantlydifferentbetweenthetwogroups.
Theplasmaglucoseresponsesatthesecond
and third OGTTs were signiﬁcantly greater
at all times in progressors than in the non-
progressors. The insulin and C-peptide lev-
els and AUCs were slightly higher at the
third OGTT in progressors than in the
nonprogressors.
Anthropometric changes
Trajectories for BMI, BMI Z score, and
percent total fat across the follow-up pe-
riodwereanalyzedtocomparetheratesof
Table 1—Demographic and anthropometric characteristics of the study participants at
baseline
Nonprogressors Progressors P
Sex (%) 0.53
Male 15 (32.6) 6 (42.9)
Female 31 (67.4) 8 (57.1)
Race (%) 0.69
Caucasian 18 (39.1) 4 (28.6)
African American 13 (28.3) 4 (28.6)
Hispanic 15 (32.6) 6 (42.8)
Family history of obesity 43 (96) 12 (86) 0.24
Family history of type 2 diabetes 16 (36) 4 (29) 0.75
Tanner stage 2–3 2–3 0.84
Age (years) 12.3  3.1 12.3  3.5 0.97
Height (m) 155.6  14.2 153  18.7 0.64
Weight (kg) 87.4  27.9 85.2  30.8 0.81
BMI (kg/m
2) 35.1  7.3 34.9  6.2 0.91
BMI Z score 2.45  0.34 2.53  0.33 0.45
Percent fat 43.9  6.2 48.7  7.5 0.07
Systolic blood pressure (mmHg) 119.8  12.7 123  11.3 0.46
Diastolic blood pressure (mmHg) 67.6  11.0 74.1  9.3 0.045*
Data are n (%) or means  SD. *P  0.05.
Table 2—Metabolic parameters of the study participants at baseline
Nonprogressors Progressors P
Fasting plasma glucose
(mmol/l) 4.92  0.05 5.27  0.11 0.002
2-h glucose (mmol/l) 6.2  0.12 6.5  0.28 0.27
Fasting insulin (pmol/l) 183.0 (130.5–229.5) 195.0 (138.0–229.5) 0.89
Proinsulin (pmol/l) 20 (14.0–32.0) 22 (13.0–25.5) 0.56
A1C (%) 5.3  0.3 5.5  0.3 0.049
SI 3.8 (1.99–9.05) 4.5 (2.1–4.5) 0.82
-Cell responsivity ()
s 68.9 (52.9–85.5) 62.5 (48.8–89.1) 0.95
d 2,514.7 (1,488.6–3,618.8) 2,001.6 (1,295.0–2,276.4) 0.04
tot 106.7 (79.1–139.8) 87.9 (77.8–119.8) 0.35
DI 612.5 (406.2–1,348.1) 545.8 (368.7–1,147.7) 0.66
Adipokines
Leptin (ng/ml) 25 (17.0–41.0) 31 (28.3–43.8) 0.02
Adiponectin (	g/ml) 6.8 (4.0–9.6) 6.9 (5.6–8.8) 0.43
IL-6 (pg/ml) 1.89 (1.1–3.1) 3.1 (1.5–4.5) 0.21
Lipids
HDL cholesterol (mmol/l) 1.05 (0.83–1.18) 1.03 (0.83–1.22) 0.96
Triglycerides (mmol/l) 1.03 (0.77–1.7) 1.13 (0.80–1.39) 0.76
Data are means  SD or median (interquartile range).
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progressors (online appendix Figure A2).
When adjusted for age, sex, race, and
family history of type 2 diabetes or obe-
sity, BMI increased signiﬁcantly in both
groups at a rate of 0.07 kg/m
2 per month
(P  0.001). Of note, the trajectories for
BMI, BMI Z score, and percent total fat
were not different over time between the
two groups (P  0.30, 0.77, and 0.14 for
BMI,BMIZscore,andpercentfat,respec-
tively).
Changes in SI, , and DI
Figure 1 compares the trajectories during
thethreeserialtestsforSI,,andDI.Data
were adjusted for age, sex, race, and fam-
ily history of type 2 diabetes and/or obe-
sity. Further analysis did not reveal sex to
be a signiﬁcant modiﬁer of any of the
three trajectories. Nevertheless, such an
interaction cannot be ruled out because
our sample size was not sufﬁcient to de-
tect such a relation.
SI trajectories showed marked differ-
ences over time between the two groups.
DespitesimilarSIatbaseline(Table2,P
0.62), in progressors, SI deteriorated over
time at a rate of 
0.02 log units per
month, which translates to a 45% reduc-
tion over 30 months compared with the
rather stable SI over 30 months in the
nonprogressors (P  0.04 for rate of
change between nonprogressors and pro-
gressors). Likewise, -cell function, mea-
sured by , decreased by 0.008 log units
per month, or a total of 20% over 30
months in progressors, whereas it re-
mained relatively stable in the non-
progressors (an increase of 5% over 30
months, P  0.09 for rate of change be-
tween the nonprogressors and progres-
sors). Of note,  was on average 25%
higher in the nonprogressors across the
follow-up period (P  0.04). When the
appropriateness of insulin secretion for
the prevailing level of SI was considered,
the DI showed a progressive decline in
progressors of 0.02 log units per month,
which translated to a 52% reduction over
30 months compared with an average
1.3% improvement over 30 months in
nonprogressors (P  0.02 for rate of
change between the nonprogressors and
progressors).
Predictors of IGT
In an additional multivariable mixed-
model analysis, SI and  were associated
with 2-h glucose changes from baseline
while age at ﬁrst visit, sex, race/ethnicity,
BMI Z score, and family history of either
obesity or type 2 diabetes were controlled
for. Each 10-unit decrease in Si was asso-
ciated with an 11 mg/dl increase in 2-h
glucose (P  0.04), and each 100-unit
decrease in  was associated with a 15
mg/dl increase in 2-h glucose (P 
0.001).
CONCLUSIONS— In the present
study, glucose, insulin, and C-peptide
plasma concentrations were measured
longitudinally during three serial OGTTs
and analyzed with the OMM to assess
both sensitivity and secretion of insulin.
Based on these measures, we provide
novelinformationabouthowglucoselev-
els change in relation to changing -cell
function and Si in a multiethnic group of
obese adolescents at high risk for type 2
diabetes.TherationaleforstudyingIGTis
based on its emergence as a relatively
common complication of adolescent obe-
sity, as well as its transitional nature as a
pre-diabetic state that may fuel the devel-
opment of type 2 diabetes in youth.
At baseline, the two groups had com-
parableageandpubertalstageofdevelop-
ment and a seemingly similar degree of
obesity. Small but signiﬁcant differences
werenotedinfastingglucoseand2-hglu-
cose AUC levels, which at baseline were
higher in progressors. Of note, SI was
similar in both groups. However, -cell
function,asindicatedbyd(18),wassig-
niﬁcantly lower in progressors than in
nonprogressors. Thus, those who pro-
gressed to IGT had relatively worse -cell
function at baseline. The present study
suggests that an early defect in -cell
function may underlie the development
of IGT in obese youth and possibly type 2
diabetes.
One could raise the point that a pos-
sible reason for differences in -cell re-
sponsivity is inaccuracy because d was
estimated with only a seven-sample
OGTT. However, our analyses tended to
exclude systematic overestimation of d
that could have affected the study’s con-
clusion. In fact, the subset of subjects
usedtoassessthereliabilityofd,s,and
tot estimated without the 10- and 20-
min samples contained both progressors
andnonprogressors,andanalysisshowed
the same 30% average overestimation of
d in both groups. Given the good corre-
lation between the estimates for samples
bothincludingandexcludingtime10and
20, a 30% overestimation of d should
likelyreﬂectonlyontheparametervalues
reported in the two groups—not on the
difference assessed at baseline.
During the 30 months of follow-up,
SIand-cellresponsivitysigniﬁcantlyde-
creased in progressors, whereas it did not
change in nonprogressors. Progressors
had a 20% reduction in -cell function
from baseline value by the third evalua-
tion. Interestingly, SI showed markedly
different trajectories in the two groups
duringtheentirestudy.SIdeclinedmark-
edly in progressors, who had values that
were45%lowerthanbaselinebythethird
OGTT after all the subjects had transi-
tioned to IGT. In contrast, for those who
retainedNGTstatus,SIremainedremark-
ably stable. When considering the in-
teraction between changes in insulin se-
cretion and SI, we found that the trajec-
toryfortheDIinprogressorsmirroredthe
clear pattern of gradual decline in both SI
and secretion. Thus, the initial fragility of
Figure 1— SI (A), tot (B), and DI (C) trajectories during the three serial OGTTs in progressors (straight line) and nonprogressors (dashed line).
Cali and Associates
DIABETES CARE, VOLUME 32, NUMBER 3, MARCH 2009 459-cell function became even more pro-
nounced with the progressive worsening
of insulin resistance in the obese adoles-
cents who developed IGT.
Evidence that declines in -cell func-
tion, SI, and DI (20) are critical determi-
nants of deteriorating glucose tolerance is
consistent with ﬁndings from adult stud-
ies in Pima Indians (21), the Insulin Re-
sistanceAtherosclerosisStudy(1,22),and
a study in Hispanic women (23). The
mechanism underlying the progressive
decline in -cell function is not fully un-
derstood. It may be related to a genetic
predisposition compounded by environ-
mental factors such as increased caloric
intake and the development of obesity.
Kahn et al. (24) showed that the develop-
ment of central adiposity was associated
with loss of -cell function, suggesting
that changes in central or visceral fat–
derived factors may predispose high-risk
individuals to -cell dysfunction. Re-
cently, Goran et al. (25) reported, in a
very interesting paper, progressive SI de-
terioration and an increase in visceral fat
content in obese Hispanic children with
persistent pre-diabetes.
Surprisingly, adiponectin levels did
not reﬂect the changes in SI that we ob-
served in progressors. We have no expla-
nation for the lack of changes in this
adipokine; perhaps it is because we mea-
sured only total adiponectin and not its
active high–molecular-weight form.
Limitationsofthecurrentstudyareits
relatively short period of follow-up time,
its small sample size, and the fact that we
usedsubjectsdrawnfromapediatricobe-
sity clinic. On the other hand, strengths
include its use of three consecutive serial
OGTTs and determination of insulin sen-
sitivityandsecretionusingtheOMMdur-
ing the subjects’ transition from NGT
to IGT.
Inconclusion,obeseadolescentswho
progress to IGT manifest primary defects
in -cell function. In addition, progres-
sive decline in Si further aggravates -cell
function, contributing to the worsening
of glucose intolerance. This longitudinal
study suggests that prevention of type 2
diabetes in obese youth should start very
early, targeting both insulin resistance
and -cell dysfunction.
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